Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

ARQ-621 well tolerated to date in phase I study

May 7, 2010

S*BIO and Onyx expand collaboration agreement for JAK2 inhibitors

May 6, 2010

FDA conducts safety review of GnRH agonist use in men with prostate cancer

May 6, 2010

INNO-206 shrinks human tumors in an animal model of multiple myeloma

May 6, 2010

AdventRx presents 6-month stability data for ANX-530

May 6, 2010

Celator reports data from phase II Cpx-351 study in acute myeloid leukemia

May 5, 2010

Curis completes enrollment and treatment in phase I study of CUDC-101 in cancer

May 5, 2010

NOXXON completes first phase I study of Spiegelmer NOX-A12

May 5, 2010

Pan-CDK inhibitor BAY-1000394 exhibits favorable pharmacologic profile in preclinical evaluation

May 5, 2010

Preclinical data on nucleolin-binding peptide EP-302 support further development in cancer therapy

May 5, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...